Nothing said here yet.
to join the conversation.
| Dube Eric MCHIEF EXECUTIVE OFFICER | Sell | 128,065 | $6.8M | Thu, Oct 15 |
| Dube Eric MCHIEF EXECUTIVE OFFICER | Sell | 78,400 | $4.3M | Thu, Oct 15 |
| Dube Eric MCHIEF EXECUTIVE OFFICER | Sell | 37,270 | $2.0M | Thu, Oct 15 |
| Dube Eric MCHIEF EXECUTIVE OFFICER | Sell | 101,691 | $6.6M | Thu, Sep 17 |
| Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | Sell | 8,282 | $538.9K | Thu, Sep 17 |
| Dube Eric MCHIEF EXECUTIVE OFFICER | Sell | 6,802 | $441.8K | Thu, Sep 17 |
| Dube Eric MCHIEF EXECUTIVE OFFICER | Sell | 99,716 | $6.3M | Wed, Sep 16 |
| Dube Eric MCHIEF EXECUTIVE OFFICER | Sell | 96,125 | $6.1M | Wed, Sep 16 |
| Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | Sell | 93,604 | $5.9M | Wed, Sep 16 |
| Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | Sell | 79,113 | $5.0M | Wed, Sep 16 |
| ROTE WILLIAM E.Chief Research Officer | Sell | 65,104 | $4.1M | Wed, Sep 16 |
| ROTE WILLIAM E.Chief Research Officer | Sell | 47,746 | $3.0M | Wed, Sep 16 |
Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In late September and early October 2026, Travere Therapeutics reported new FILSPARI® (sparsentan) data across IgA nephropathy and FSGS at ASN Kidney Week and secured extended U.S. patent protection for FILSPARI use in these rare kidney diseases into 2037.
Travere Therapeutics (NasdaqGM:TVTX) announced a planned CEO and President transition effective December 1, 2026. Dr. Eric Dube will step down from his roles as CEO and President as part of the scheduled leadership change. Bradley L.
Travere Therapeutics has delivered a very large share price gain over the past few years, which naturally puts the focus on what investors are paying for its sales today.